Jr., James F. Haley

Massachusetts

New York

U.S. Patent and Trademark Office

Partner

Ropes & Gray

Current

Current

Jimhas handled numerous United States and foreign patent litigations, European and other patent oppositions and United States interferences in biotechnology and biopharmaceuticals. Some of his representative infringement cases include: MEEI v. QLT/Novartis Ophthalmics, Civil Action 01-CV-10747-EFH (D. Mass), MEEI v. QLT, Civil Action 00-CV-10783-JLT (D. Mass) Amgen v. Aventis/TKT (US), Oregon Health Sciences University v. Vertex Pharmaceuticals, Inc., Civil Action 01-CV-1272-HU (D. Oregon), Biogen v. Berlex (US), Pieczenik v. Dyax (US), Biogen v. Amgen (US), Biogen v. Thomae (Germany), Biogen v. Bender (Austria), Biogen v. BTG (Israel), Biogen v. Medeva (UK), Yamanouchi v. Biogen (France, Italy, Netherlands and Germany), Biogen v. Scitech (Singapore), Biogen v. Amgen (Japan), Biogen and Harvard University v. Sumitomo (Japan), Biogen and Harvard University v. Pharmacia (Sweden), Biogen v. Pharmacia (US), Schering-Plough v. Sterling Winthrop (US), Boehringer Ingelheim v. Bioferon (Germany), Sheller Globe v. Milsco (US), Square D v. 3M (US), PPG v. Celanese (US), Case v. BASF (US), Amgen v. TKT/Aventis (UK), Biogen v. BTG (Israel). Jim's representative oppositions include: EPO (IL-1 Inhibitor), EPO (phage display), EPO (expression vector), EPO (alpha interferon), EPO (hepatitis B viral antigens), EPO (gamma interferon), EPO (beta interferon), Germany (beta interferon), EPO (protein secretion),EPO (xenomice and antibodies), EPO (imaging agents), Australia (gamma interferon), Australia (antiviral compounds), Japan (beta interferon), Japan (protein secretion), Japan (alpha interferon), Japan (antiviral nucleosides). Jim's representative interferences include: alpha interferon, hepatitis B viral antigens, protein secretion, leukocyte adhesion molecules, beta interferon, interleukin 1 converting enzyme inhibitors, and bone morphogenic proteins, CD40 counterreceptor antibodies, transgenic fibrinogen. Jim counsels clients on intellectual property protection and licensing of patents and technology. He has extensive experience in the United States and worldwide patent prosecution in all areas of biotechnology and biopharmaceuticals. Patents he has prepared and prosecuted have earned clients more than4 billion dollars in royalties.

Suffolk University Law School

J.D.

1975

magna cum laude, Member, Law Review

Brandeis University

Ph.D.

1975

Organic Chemistry

Brandeis University

M.A.

1969

Chemistry

University of Notre Dame

B.S.

1967

Chemistry